Vaccines in Virology: New Developments and Pathogen Response
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Microbiology".
Deadline for manuscript submissions: closed (15 March 2024) | Viewed by 669
Special Issue Editor
Special Issue Information
Dear Colleagues,
In recent years, the emergence of pathogens such as Ebola virus, COVID-19, monkey pox, VDPV2 and wild poliovirus type 1 has challenged not only the production of new vaccines, but also vaccination programs. These emergencies have led to the introduction of new vaccines in stage III trials under the WHO EUL (Ebola, COVID-19 19, nOPV2). This has been controversial on several levels. For example, (i) local populations do not readily accept being used as guinea pigs; (ii) conspiracy theories have been recently risen in popularity (COVID-19). The emergence of monkey pox cases in previously unaffected continents raises the issue of stopping vaccination after the pathogens have been eradicated. The reintroduction of wild poliovirus type 1 in Africa questions the quality of disease surveillance and supplementary immunization activities. Other issues related to the administration of vaccines to people who have undergone organ transplants or cancer treatment, not to mention the changes in the epidemiology of pathogens that have been under vaccine pressure for years, are just as topical. Will mass vaccination solve all our problems related to the emergence and re-emergence of viruses? Will a population that has more and more access to information (or disinformation, for that matter) easily accept new vaccines? How can the adverse effects of vaccines be explained without creating mistrust? How can we explain the efficacy of vaccines and the benefits of selective vaccination to an increasingly individualistic world?
This is a small sample of the questions that the scientific world should be able to answer so that neither the efforts to combat vaccine-preventable viral diseases nor the progress made remain in vain or ineffective.
Dr. Ionela Gouandjika-Vasilache
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- virus
- vaccine
- emergence
- epidemiology
- adverse effects
